Molecular Biology Program

The Dirk Remus Lab

Share
Back to top

Research

Dirk Remus
Dirk Remus, PhD


Professor

We are interested in the mechanism of chromosome replication, a process that is highly conserved across eukaryotes and that involves the duplication of both the chromosomal DNA and its associated chromatin states. As chromosomes are the carriers of both the genetic and epigenetic information, faithful chromosome replication is of fundamental importance for genome maintenance during normal cell proliferation. Accordingly, defects in chromosome replication are a major driver of the genomic instability observed in cancer cells. To understand the molecular mechanisms by which eukaryotic cells carry out and monitor accurate genome replication we employ a fully reconstituted DNA replication system based on purified proteins from the budding yeast, S. cerevisiae. Research projects are focused on the mechanistic characterization of the DNA replication machinery, the mechanism of replication-coupled chromatin assembly, and the control of DNA replication by checkpoint genome surveillance pathways.

View Lab Overview

The Dirk Remus Lab

Featured News

Dirk Remus and Richard Hite
SKI Scientists Determine Structure of a DNA Damage 'First Responder'
The results of this collaborative project overturn some conventional wisdom about how the DNA repair process works.
Pictured: Dirk Remus
At Work: Molecular Biologist Dirk Remus
Molecular biologist Dirk Remus studies how cells normally copy their DNA to better understand how the process goes wrong in cancer.

Publications Highlights

Multistep loading of a DNA sliding clamp onto DNA by replication factor C. Schrecker M, Castaneda JC, Devbhandari S, Kumar C, Remus D, Hite RK. Elife. 2022 Aug 8;11:e78253. doi: 10.7554/eLife.78253.

CMG helicase activity on G4-containing DNA templates. Batra S, Devbhandari S, Remus D. Methods Enzymol. 2022;672:233-260. doi: 10.1016/bs.mie.2022.02.020. Epub 2022 Mar 25.

Yeast ORC sumoylation status fine-tunes origin licensing. Regan-Mochrie G, Hoggard T, Bhagwat N, Lynch G, Hunter N, Remus D, Fox CA, Zhao X. Genes Dev. 2022 Aug 4. doi: 10.1101/gad.349610.122. Online ahead of print.

A hypomorphic mutation in Pold1 disrupts the coordination of embryo size expansion and morphogenesis during gastrulation. Chen T, Alcorn H, Devbhandari S, Remus D, Lacy E, Huangfu D, Anderson KV. Biol Open. 2022 Aug 15;11(8):bio059307. doi: 10.1242/bio.059307. Epub 2022 Aug 8.

Scherr MJ, Wahab SA, Remus D, Duderstadt KE. Mobile origin-licensing factors confer resistance to conflicts with RNA polymerase. Cell Rep. 2022 Mar 22;38(12):110531. doi: 10.1016/j.celrep.2022.110531.

View All Publications

People

Dirk Remus

Dirk Remus, PhD



Professor

  • Molecular biologist Dirk Remus investigates mechanisms of DNA replication in eukaryotic cells.
  • PhD, University of California, Berkeley
[email protected]
Email Address
212-639-5263
Office Phone

Members

Lisbelle Adorno

Administrative Assistant

Sujan Devbhandari
Sujan Devbhandari

Postdoctoral Fellow

Charanya Kumar

Postdoctoral Associate

Sahil Batra
Sahil Batra

Research Scholar

Juan Castaneda
Juan Castaneda

Graduate Student

Sumedha Dahal

Research Scholar

Tenzing Dakpa

Research Technician

Lucia Wang
Lucia Wang

GSK Graduate Student

Lab Alumni
Melissa Chan

Research Technician

Julien Gros

Research Fellow

Gerard P. Lynch
Gerard P. Lynch

Research Fellow

Ademola Adegbemigun
Ademola Adegbemigun

Research Technician

Syafiq Abd Wahab
Syafiq Abd Wahab

Graduate Student

Lab Affiliations

Achievements

  • Louis V. Gerstner, Jr. Young Investigator Award, Memorial Sloan Kettering Cancer Center (2011)
  • Long-Term Fellow, EMBO (2006)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Dirk Remus discloses the following relationships and financial interests:

  • AbCellera Biologics Inc.
    Equity
  • Advanced Micro Devices, Inc
    Equity
  • Alphabet Inc
    Equity
  • Alpine Immune Sciences, Inc.
    Equity
  • Beam Therapeutics
    Equity
  • CRISPR Therapeutics AG
    Equity
  • Ginkgo Bioworks, Inc.
    Equity
  • INmune Bio, Inc.
    Equity
  • Intellia
    Equity
  • Merck & Co Inc.
    Equity
  • Microsoft Corporation
    Equity
  • Moderna, Inc.
    Equity
  • Novo Nordisk
    Equity
  • NVIDIA Corporation
    Equity
  • Pfizer, Inc.
    Equity
  • Prime Medicine, Inc.
    Equity
  • Recursion Pharmaceuticals
    Equity
  • Repare Therapeutics
    Equity

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures